Is CTSO a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for CytoSorbents Corporation (CTSO) rests on Operating cash flow at breakeven: The first goal management set for 2026 was to stop burning cash, and the Q3 numbers say it got there. The bear case rests on financing is still the largest risk, though the November 2026 deal changed its shape. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
CTSO key stats
At $4.16 on November 20, 2026, CytoSorbents Corporation (CTSO) has a market cap of $13M.
- Market cap
- $13M
Market cap, P/E and yield are measured at the $4.16 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with CytoSorbents Corporation (CTSO)?
The last two weeks for CytoSorbents Corporation, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.
- CTSO closed at $4.16 on November 20, 2026, down 14.6% over the past five trading days (from $4.87).
Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
CytoSorbents makes porous polymer beads packed into cartridges that clip into a blood circuit and pull inflammatory molecules, toxins and some drugs out of a patient's blood. Its main product, CytoSorb, is approved in the European Union and distributed in more than 70 countries, where intensive care units use it in septic shock and cardiac surgeons use it during bypass procedures. The company also owns DrugSorb-ATR, a version aimed at removing the blood thinner Brilinta (ticagrelor) during urgent heart surgery, which is not yet authorized in the United States, and HemoDefend-BGA, an early program meant to make universal plasma. Nearly all revenue comes from outside the U.S.: in the third quarter of 2026 American sales were about $70,000 out of $9.7 million. The Q3 2026 report, filed November 12 and corrected on November 19, showed revenue up ~3% year over year to ~$9.7 million, with distributor and partner sales up ~18% and German sales down ~21% after a sales force cut. Gross margin rose to ~75% from ~70%. Operating expenses fell ~11% to ~$8.5 million, the operating loss narrowed to ~$1.2 million, and the company reported roughly breakeven operating cash flow excluding restructuring payments. For the nine months, revenue was ~$28.2 million and net loss ~$12.0 million, inflated by a ~$2.5 million non-cash currency loss. The 10-Q was filed late, after a review of how those currency losses were calculated, and management reported continuing material weaknesses in internal controls. The investment picture is dominated by the balance sheet. At September 30 the company had ~$4.2 million of unrestricted cash plus ~$1.5 million restricted, against ~$17.5 million of Avenue Capital debt that was due to start amortizing after December 31, 2026 and mature July 1, 2027. Stockholders' equity was a deficit of ~$2.3 million and the 10-Q carries a going-concern warning. On November 20, 2026 the company announced a ~$6.25 million package: a ~$4.0 million registered direct offering at $4.94 a share (insiders paid $5.18), about 75% taken up by existing holders, management and the board, plus ~$2.25 million of loan principal repaid in stock to Avenue. Principal fell to ~$12.25 million, interest-only payments now run to March 31, 2028, and maturity moved to July 1, 2028. The stock went through a 1-for-20 reverse split on September 8, 2026 and has traded between ~$2.84 and ~$17.00 (split-adjusted) over the past year. It closed at ~$4.39 on November 20, down ~66.5% year to date and ~64.7% over twelve months, for a market value of ~$14 million on the pre-offering share count, well below the $35 million Nasdaq requires, with a compliance deadline of December 28, 2026.
The bull case for CTSO
1. Operating cash flow at breakeven
The first goal management set for 2026 was to stop burning cash, and the Q3 numbers say it got there. Q3 net loss of ~$1.83 million, or ~-$0.58 a share, was narrower than the ~-$0.90 analysts expected, the first beat after three quarters of wider-than-forecast losses. Operating cash flow was about +$43,000 excluding ~$251,000 of restructuring payments, against a burn of ~$2.7 million in Q3 2025. Total cash burn including restructuring was ~$200,000. The levers were a ~24% headcount cut since September 2025, cheaper manufacturing that lifted gross margin to ~75%, and inventory reduced from ~$5.3 million at year end to ~$3.2 million. Some of that inventory drawdown is one-time, so the next few quarters will show whether breakeven holds when working capital stops releasing cash and the company begins rehiring sales staff in Germany.
2. Returning CytoSorb to growth
Total revenue has been close to flat for two years, at ~$35.6 million in 2024 and ~$37.1 million in 2025, with nine-month 2026 revenue up only ~1.4%. Inside that, the mix is shifting. Distributor and strategic partner sales, about half of Q3 revenue at ~$5.1 million, grew ~18%, and direct sales outside Germany rose ~5%. Germany, once a third of sales, fell to ~23% of the quarter after territory cuts. The company has added two German representatives, plans three more by early 2027 and hired a new head of direct sales. With ~75% gross margins, every added dollar of sales carries most of its value to the bottom line if expenses stay near ~$8.5 million a quarter.
3. DrugSorb-ATR and the U.S. market
DrugSorb-ATR is the company's route into the United States. The FDA denied the original De Novo application and upheld that denial on appeal in August 2025, citing no safety concerns but asking for more real-world evidence. The company now plans a new submission in early 2027, built on the STAR-T trial (published in the Journal of Thoracic and Cardiovascular Surgery), an independent 587-patient matched analysis showing severe bleeding of ~21.8% with CytoSorb versus ~34.5% without, and an animal study whose protocol still needs FDA sign-off. A second filing for Eliquis and Xarelto removal is planned. Management sizes the initial U.S. and Canadian market at ~$300 million; that figure is the company's estimate, and any decision would follow a review of roughly 150 days.
4. HemoDefend-BGA as a separate asset
HemoDefend-BGA is designed to strip anti-A and anti-B antibodies from plasma and platelets so a single product could be given to patients of any blood type. It was developed with ~$16 million of U.S. government funding and received FDA feedback on a clinical pathway in July 2026. Management says it will look for more grant money, a partner, a license or another strategic deal for the program, so that it does not drain the core business. For a company valued at ~$16 million, any upfront payment from a licensing deal could matter to the balance sheet, though no agreement has been announced and the product is still years from potential approval.
The bear case for CTSO
Financing is still the largest risk, though the November 2026 deal changed its shape. Avenue Capital debt fell from ~$17.5 million to ~$12.25 million, interest-only payments were extended to March 31, 2028 (three more months if DrugSorb-ATR is approved by then) and maturity moved to July 1, 2028; the company puts interest savings at ~$0.7 million over twelve months. Avenue can now convert up to ~$3.0 million of principal at $6.916 a share, and another ~$3.125 million at $8.645 from the earlier of DrugSorb-ATR approval or January 1, 2028, so further dilution is built in. Most of the ~$4.0 million of new cash went to repaying ~$3.0 million of principal plus fees, which leaves the company relying on breakeven operations. Listing is the second risk: the market value is far below Nasdaq's $35 million minimum, the December 28, 2026 deadline is close, and the new shares add equity but the company itself says there is no assurance it keeps the listing. Accounting is a third: material weaknesses persist, and the Q3 10-Q was filed late after a currency loss error; the first release understated nine-month net loss by ~$0.6 million. Regulatory risk remains, because the FDA has already turned down DrugSorb-ATR once, and the business depends heavily on German and European hospital budgets.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding CTSO already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on CTSO
Too few analysts publish on CTSO for a consensus target to mean anything, so there is no professional average to weigh against your own view. That cuts both ways: less informed opinion to lean on, and less of it already priced in. The CTSO forecast page covers what coverage does exist.
How is CTSO valued?
Market cap, P/E and dividend yield at today's price are in the CTSO key stats above. The business figures below come from CytoSorbents Corporation's reported results as of November 2026 and change when it next reports.
- Revenue (TTM): ~$37.5 million
- Revenue growth (Q3 2026, yoy): ~+2.6%
- Gross margin (TTM): ~73%
- Net loss (TTM): ~-$16.9 million
- Avenue debt after Nov 2026 amendment: ~$12.25 million, due July 2028
As of November 2026: At ~$4.39 the stock trades at roughly 0.4 times trailing sales, a level usually seen in medical device companies with serious balance sheet problems. Earnings ratios do not apply: trailing net loss is ~$16.9 million, much of it from non-cash currency swings and interest, and analysts expect a ~-$3.72 per-share loss for 2026. The November 2026 amendment cut the Avenue loan to ~$12.25 million and moved the maturity to July 2028, so the valuation now rests more on whether a business near cash breakeven with ~73-75% gross margins can grow toward the ~$44 million of 2027 revenue analysts forecast.
How do you decide if CTSO is a buy?
Whether CTSO is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold CTSO indirectly through an index or sector ETF before adding more.
What would change your mind on CTSO
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Operating cash flow at breakeven stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: financing is still the largest risk, though the November 2026 deal changed its shape fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the CTSO stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about CTSO against your real portfolio and see your actual exposure before deciding.
Your questions about CytoSorbents Corporation
Ask Walnut's AI anything about CTSO and see how it fits what you own.
FAQ
Is CTSO a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Operating cash flow at breakeven, with revenue (ttm) at ~$37.5 million. The bear case rests on financing is still the largest risk, though the November 2026 deal changed its shape. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell CTSO?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Financing is still the largest risk, though the November 2026 deal changed its shape. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. Walnut is not an investment adviser.
What is the bull case for CTSO?
+
Operating cash flow at breakeven. The first goal management set for 2026 was to stop burning cash, and the Q3 numbers say it got there.
What is the bear case for CTSO?
+
Financing is still the largest risk, though the November 2026 deal changed its shape. Avenue Capital debt fell from ~$17.5 million to ~$12.25 million, interest-only payments were extended to March 31, 2028 (three more months if DrugSorb-ATR is approved by then) and maturity moved to July 1, 2028; the company puts interest savings at ~$0.7 million over twelve months. Avenue can now convert up to ~$3.0 million of principal at $6.916 a share, and another ~$3.125 million at $8.645 from the earlier of DrugSorb-ATR approval or January 1, 2028, so further dilution is built in. Most of the ~$4.0 million of new cash went to repaying ~$3.0 million of principal plus fees, which leaves the company relying on breakeven operations. Listing is the second risk: the market value is far below Nasdaq's $35 million minimum, the December 28, 2026 deadline is close, and the new shares add equity but the company itself says there is no assurance it keeps the listing. Accounting is a third: material weaknesses persist, and the Q3 10-Q was filed late after a currency loss error; the first release understated nine-month net loss by ~$0.6 million. Regulatory risk remains, because the FDA has already turned down DrugSorb-ATR once, and the business depends heavily on German and European hospital budgets.
What does CytoSorbents Corporation do?
+
Princeton, New Jersey maker of CytoSorb, a blood purification cartridge used in intensive care and cardiac surgery, sold mostly in Europe.
What would have to change for CTSO to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Operating cash flow at breakeven) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (financing is still the largest risk, though the November 2026 deal changed its shape) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does CytoSorbents do?
+
CytoSorbents develops and sells blood purification cartridges filled with porous polymer beads. When blood passes through the cartridge, the beads capture molecules in a certain size range, including inflammatory cytokines, bilirubin, myoglobin and some drugs. The flagship product, CytoSorb, has European Union approval and is used in intensive care for conditions such as septic shock and in cardiac surgery during bypass. The company is based in Princeton, New Jersey, manufactures there and runs its main European subsidiary in Berlin, Germany. Its pipeline includes DrugSorb-ATR, which targets blood thinner removal during urgent heart surgery, and HemoDefend-BGA, which aims to make universal plasma and platelets. Almost all sales are outside the United States, where the company sold only about $70,000 of product in the third quarter of 2026.
Is CytoSorbents profitable?
+
No. The company has lost money every year, with net losses of ~$20.7 million in 2024 and ~$8.2 million in 2025. For the first nine months of 2026 the net loss was ~$12.0 million, or ~$3.82 per share, though ~$2.5 million of that was a non-cash currency loss and ~$2.6 million was interest. The operating loss is narrowing quickly: it was ~$1.2 million in Q3 2026 versus ~$2.9 million a year earlier, and adjusted EBITDA loss shrank to ~$0.3 million. The company reported roughly breakeven operating cash flow in Q3 excluding restructuring payments. Gross margin of ~75% is high for a device maker, so profitability depends mostly on sales growth and on interest costs once the debt is dealt with.
Walnut is informational, not investment advice, and gives no verdict on CTSO. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.